Skip to main content
Andrew Kaz, MD, Gastroenterology, Seattle, WA

AndrewMichaelKazMD

Gastroenterology Seattle, WA

Associate Professor, Medicine, University of Washington School of Medicine

Dr. Kaz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kaz's full profile

Already have an account?

  • Office

    1660 S. Columbian Way
    S-111-Gastro
    Seattle, WA 98108
    Phone+1 206-764-2285

Summary

  • Andrew Kaz, MD is a gastroenterologist based in Seattle, WA, and serves as an Associate Professor at the UW Medicine/University of Washington Medical Center since 2019. He completed his medical education at Duke University, residency in Internal Medicine at the University of Michigan, and fellowship in Gastroenterology at the University of Washington. Dr. Kaz is experienced in esophageal disease, colonic neoplasms, and adenocarcinoma. His research includes several published studies, such as a notable contribution on the detection of esophageal adenocarcinoma and his involvement in multiple clinical trials, including those addressing treatments for GERD and colorectal cancer.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Gastroenterology, 2003 - 2007
  • University of Michigan
    University of MichiganResidency, Internal Medicine, 1999 - 2002
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1999

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2003 - 2026
  • MI State Medical License
    MI State Medical License 1999 - 2006
  • Gastroenterology
    American Board of Internal Medicine Gastroenterology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Novel Barrett’s Esophagus Screening Assays Based on Swallowable Devices: Will They Change the Game?
    Novel Barrett’s Esophagus Screening Assays Based on Swallowable Devices: Will They Change the Game?April 1st, 2019

Grant Support

  • Methylated DNA Biomarkers For Barrett'S Esophagus And Esophageal AdenocarcinomaNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2011